Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05223205
Other study ID # 32-465 ex 19/20
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 6, 2020
Est. completion date June 6, 2023

Study information

Verified date September 2023
Source Medical University of Graz
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

State of the art treatment for idiopathic macular holes consists of pars plana vitrectomy, internal limiting membrane staining with a blue colouring dye, internal limiting membrane peeling and filling of the vitrectomized space with a specific tamponade such as air and SF6. Air and SF6 have previously shown similar closure rates, although there was a trend towards lower closure rates in large diameter IMH (Idiopathic Macular Holes) using air. IMH with diameters < 600 μm are currently believed to have similar closure rates with air and SF6. The investigators want to assess possible effects of the used tamponade (air or SF6) on closure rates and perfusion parameters represented by OCTA (Optical coherence tomography angiography). IMH eyes with a minimum diameter > 600 μm will be excluded. Two idiopathic macular hole patient groups will therefore be formed: The first group (group 1) will receive air after vitrectomy and membrane peeling, the second group (group 2) will receive 10% SF6 (and 90% air) after vitrectomy and membrane peeling. After recruitment, patients will therefore be electronically randomized to one of the two groups. The groups will then be compared by the means of OCT (Optical coherence tomography) and OCTA. Note: The trial was registered retrospectively on Clinicaltrials.gov after start of recruitment.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date June 6, 2023
Est. primary completion date February 6, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Patient must be able and willing to give informed consent. - Patient must be between 18 and 100 years of age. - Patient must not have any significant media opacity which interferes with the examination. - Patient must have an (stage 1-4) idiopathic macular hole requiring surgery. Exclusion Criteria: - Unwilling or unable to provide informed consent - Under 18 or over 100 years of age - Significant media opacities - Systemic pathologies making an examination difficult or cumbersome to the patient - Primary and/or secondary epiretinal membranes (ERM), except incipient ERMs not affecting the foveal contour and not requiring surgery - Full-thickness idiopathic macular hole > 600 µm in minimum diameter - Nonclosure - Lamellar holes not requiring surgery - Pseudo holes - Glaucoma - Diabetes - Anisometropia > 2 diopters - High myopia (spherical equivalent > 6 diopters and/or axial length > 26 mm - Other retinal or ophthalmic pathologies except moderate cataract - OCTA scan signal strength < 5 - Low image quality - Failure of automatic layer segmentation

Study Design


Intervention

Procedure:
Air
Test if air is sufficient for macular hole closure.
10% SF6 and 90% air
Test if 10% SF6 and 90% air is sufficient for macular hole closure.

Locations

Country Name City State
Austria Department of Ophthalmology Graz Styria

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Graz

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Macular hole closure 2 weeks
Secondary Foveal avascular zone area 3 months
Secondary Parafoveal vessel density 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT04535622 - Efficacy of Exercise Program for Facedown Posture-related Pain After Retinal Surgery N/A
Completed NCT03572725 - Air Tamponade and Non-supine Positioning in Macular Hole Surgery. N/A
Completed NCT01471912 - Elongation of Foveal Tissue After Macular Hole Surgery N/A
Completed NCT03646695 - ILM Flap Transposition Versus ILM Peeling for Macular Holes: a Pilot Study N/A
Completed NCT06323902 - Autologous Platelet-rich Plasma as a Treatment for Macular Holes
Completed NCT01974310 - Postoperative Positioning After Surgery for Macular Holes N/A
Completed NCT00537992 - Blue-Blocking IOLs in Combined Surgery N/A
Completed NCT05171621 - Measuring Subjective Quality of Vision and Metamorphopsia Before and After Epiretinal Membrane and Macular Hole Surgery
Recruiting NCT06000111 - Duration of Face Down Positioning for Full-Thickness Macular Hole Repair N/A
Recruiting NCT04135638 - Inverted ILM-flap Techniques Variants for Macular Hole Surgery: Outcomes Comparison N/A
Completed NCT03525899 - Macular Hole After Diabetic Vitrectomy
Completed NCT03917602 - Human Amniotic Membrane Plug for Large Macular Holes N/A
Completed NCT04527848 - Comparison of Two Intraocular Gas Injection Techniques in Macula Hole Surgery Phase 4
Recruiting NCT04116892 - Comparative Analysis of Large Macular Hole Surgeries N/A
Completed NCT01229657 - Evaluation of Anatomic and Visual Outcomes of Initially Closed Macular Holes N/A
Completed NCT01306487 - Observation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery N/A
Completed NCT01381965 - Foveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery N/A
Completed NCT03174639 - High Myopia Macular Hole and Retinal Detachment Treated With Double ILM Flaps N/A
Recruiting NCT05083650 - Large Macular Hole Closure Rate With Amniotic Membrane Graft With and Without Limitorrhexis N/A